EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab By Ogkologos - May 8, 2026 10 0 Facebook Twitter Google+ Pinterest WhatsApp It is a cancer medicine used to treat adult patients with multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC EMA Recommends Extension of Indications for Dabrafenib and Trametinib MOST POPULAR Study Improves the Quality of Biopsy Specimens for Cancer Research October 23, 2018 Opinion: ‘Beating cancer means beating it for everyone’ January 29, 2021 Italian Association of Oncology Nurses Maps the Situation of Cancer Patients... July 23, 2020 Finding Hope in the New Year During COVID-19 and Cancer January 6, 2021 Load more HOT NEWS TAT 2021 Honorary Award: A Recognition in Cancer Drug Development to... EMA Recommends Granting a Marketing Authorisation for Akeega, Fixed-Dose Combinations of... Active Surveillance for Low-Risk Prostate Cancer Continues to Rise Ενθαρρυντικά δεδομένα για ασθενείς με προχωρημένο μελάνωμα που έλαβαν θεραπεία με...
